Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21142421 | 0.90 | CYP2D6 (0.40) | CYP1A2CYP2D6CYP2C19ALDH1A1MAPT | |
| SCHEMBL20072419 | 0.88 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C19NR1I2NPSR1 | |
| SCHEMBL30442907 | 0.87 | ALDH1A1 (0.36) | CYP2D6NR1I2ALDH1A1MAPTHTT | |
| SCHEMBL23169104 | 0.86 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP2C19NR1I2NPSR1 | |
| SCHEMBL20746911 | 0.86 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP2C19NR1I2NPSR1 | |
| SCHEMBL18426652 | 0.85 | ALDH1A1 (0.43) | CYP2D6ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL20862381 | 0.82 | PLAT (0.44) | NR1I2ALDH1A1KDM4E | |
| SCHEMBL22306322 | 0.82 | IDO1 (0.41) | CYP1A2CYP2D6CYP2C19ALDH1A1IDO1 | |
| SCHEMBL20862648 | 0.81 | NR1I2 (0.40) | NR1I2ALDH1A1MAPTHTTKDM4E | |
| SCHEMBL4839441 | 0.81 | ALDH1A1 (0.42) | CYP1A2CYP2D6CYP2C19ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | CYP1A2 2559/4885CYP2D6 3850/4885CYP2C19 4261/4885 |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CYP1A2 429/4885CYP2D6 787/4885CYP2C19 810/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | CYP1A2 3989/4885CYP2D6 4257/4885CYP2C19 4423/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | CYP1A2 2559/4885CYP2D6 3850/4885CYP2C19 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.